Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 1, 1996, Pages 271-276

  Peter, Chennekatu P ^a   Guy, Jeff ^b   Shea, Marie ^b   Bagdon, Walter ^c   Kline, Walter F ^a   Hayes, Wilson C ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MASS; BONE REMODELING; BONE STRENGTH; CALCIUM BLOOD LEVEL; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; LONG TERM CARE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; TOXICITY TESTING;

ADMINISTRATION, ORAL; ALENDRONATE; ANIMALS; BIOMECHANICS; BODY WEIGHT; BONE AND BONES; CALCIUM; DIPHOSPHONATES; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; MALE; ORGAN SIZE; PHOSPHORUS; TIME FACTORS;

EID: 0029985680     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. ADAMI, S., SALVAGNO, G., GUARRERA, G., MONTESANTI, F., GARAVELLI,. S., ROSNI, S. AND CASCIO, V. L.: Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1-1-bisphosphonate. Calcif Tissue Int. 39: 226-229, 1986.
2. ATTARD-PARRINELO, G , MERLINI, G., PAVESI, F., CREMAA, F., FIORENTINI, M. L. AND ASCARI, E.: Effects of a new aminobisphosphonate (aminohydroxybutilidene diphosphonate) in patients with osteolytic lesions from metastases and myclomatosis: Comparison with dichloromethylene diphosphonate. Arch. Intern. Med. 147: 1629-1633, 1987.
3. BALENA, R., MARKATOS, A., SEEDOR, J. G., GENTILE, M., STARK, C., PETER, C. P. AND RODAN, G. A.. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J. Pharmacol. Exp. Ther. 276: 277-283, 1996.
4. FLEISCH, H., RUSSEL, R. G. G. AND FRANCIS, M. D.: Diphosphonates inhibit hydroxy appetite dissolution in vitro and bone resorption in tissue culture and in vivo. Science (Wash. DC) 165: 1262-1264, 1969.
5. FLORA, L., HESSING, G. S., CLOYD, G. G., SEVAN, J. A AND PARFITT, A. M.: The long-term skeletal effects of EHDP in dogs. Metab. Bone Dis. & Rel. Res. 25: 289-300, 1981.
6. FLORA, L., HESSING, G. S., PARFITT, A. M. AND VILLANUEVA, A. E.: Comparative skeletal effects of two bisphosphonates in dogs. Metab. Bone Dis. & Rel. Res. 25: 389-407, 1980.
7. GUY, J. A., SHEA, M., PETER, C. P., MORRISSEY, R. AND HAYES, W. C.: Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif. Tissue Int. 53: 283-288, 1993.
8. JEE, W. S. S., BARTLEY, M. H,. COOPER, R. R. AND DOCKUM, L.: The beagle as an experimental dog. In Bone Structure, ed by A. C. Anderson, pp. 162-188, The Iowa State University Press, Ames, 1970.
9. KLINE, W. F. AND MATUSZEWSKI, B. K.: Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolum derivatization and high performance liquid chromatography with fluorescence and electrochemical detection. J. Chromatogr. 583: 183-193, 1992.
10. LAFAGE, M. H., BALENA, R., BATTLE, M R., SHEA, M., SEEDOR, J. G., KLEIN, H., HAYES, W. C. AND RODAN, G. A.: Comparison of alendronate and sodium fluride effects on cancellous and cortical bone in minipigs. A one-year study. J. Clin. Invest. 95: in press, 1995
11. SATO, M., GRASSER, W., ENDO, N., AKINS, R., SIMMONS, H., THOMPSON, D. D., GOLUB, E. AND RODAN, G. A.: Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88: 2095-2105, 1991.
12. SEEDOR, J. G., QUARTUCCIO, H. A. AND THOMPSON, D D.: The bisphosphonate alendronate (MK-0217) inhibits bone loss due to ovariectomy in rats. J. Bone Miner Res. 6: 339-346, 1991
13. SHENK, R., EGGLI, P., FLEISH, H. AND ROSINI, S.: Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonate on bone resorption in the rat. Calcif. Tissue Int. 38: 342-349, 1986.
14. SIETSEMA, W. K., EBETINO, F. H., SALVAGNO, A. M. AND BEVAN, J. A.: Antiresorptive dose response relationships across three generations of bisphosphonates. Drugs Exp. Clin. Res. XV: 389-396, 1989.
15. THOMPSON, D. D., SEEDOR, J G., QUARTUCCIO, H. A., SOLOMON, H., FIORAVANTI, C., DAVIDSON, J , KLEIN, H., JACKSON, R., CLAIR, J., FRANKENFIELD, D., BROWN, E., SIMMONS, H. A. AND RODAN, G A : The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J. Bone Miner. Res. 7: 951-960, 1992.
16. THOMPSON, D. D., SEEDOR, J. G., WEINREB, M., ROSINI, S. AND RODAN, G. A.: Aminohydroxybutone bisphosphonate inhibits bone loss due to immobilization in rats. J. Bone Miner. Res. 5: 279-286, 1990.